Evidence map›Paper›PMID 25184625›Full record

ArticlePloS one2014

Helicobacter hepaticus infection promotes hepatitis and preneoplastic foci in farnesoid X receptor (FXR) deficient mice.

Alton G Swennes, Alexander Sheh, Nicola M A Parry, Sureshkumar Muthupalani, Kvin Lertpiriyapong, Alexis García, James G Fox

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. The development of colitis in Il10Mucosal immunology · 2020
    Article
  6. Review
  7. Article
  8. Article
  9. Journal of the American Association for Laboratory Animal Science : JAALAS · 2017
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Alton G SwennesDivision of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
Alexander ShehDivision of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
Nicola M A ParryDivision of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
Sureshkumar MuthupalaniDivision of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
Kvin LertpiriyapongDivision of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
Alexis GarcíaDivision of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
James G FoxDivision of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
Massachusetts Institute of Technology · US

Funding

TOXICOLOGY CORE UNITP30ES002109 · NIEHS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LEVINE, STUART S · 1985 to 2020
$25.6M
Reaction and Diffusion of NO in Biological SystemsP01CA026731 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI TANNENBAUM, STEVEN R · 1985 to 2018
$25.4M
Biomedical Research Training for Veterinary ScientistsT32OD010978 · OD · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI FOX, JAMES G · 2012 to 2017
$2.2M
Diagnosis and Pathobiology of Emerging Enterohepatic Helicobacter spp. in MiceR01OD011141 · OD · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI FOX, JAMES G · 2012 to 2014
$1.2M
NCI NIH HHS P01 CA026731NIEHS NIH HHS P30 ES002109NIH HHS R01 OD011141NIH HHS T32 OD010978
6 · The paper itself

Abstract

Farnesoid X receptor (FXR) is a nuclear receptor that regulates bile acid metabolism and transport. Mice lacking expression of FXR (FXR KO) have a high incidence of foci of cellular alterations (FCA) and liver tumors. Here, we report that Helicobacter hepaticus infection is necessary for the development of increased hepatitis scores and FCA in previously Helicobacter-free FXR KO mice. FXR KO and wild-type (WT) mice were sham-treated or orally inoculated with H. hepaticus. At 12 months post-infection, mice were euthanized and liver pathology, gene expression, and the cecal microbiome were analyzed. H. hepaticus induced significant increases hepatitis scores and FCA numbers in FXR KO mice (P<0.01 and P<0.05, respectively). H. hepaticus altered the beta diversity of cecal microbiome in both WT and FXR KO mice compared to uninfected mice (P<0.05). Significant upregulation of β-catenin, Rela, Slc10a1, Tlr2, Nos2, Vdr, and Cyp3a11 was observed in all FXR KO mice compared to controls (P<0.05). Importantly, H. hepaticus and FXR deficiency were necessary to significantly upregulate Cyp2b10 (P<0.01). FXR deficiency was also a potent modulator of the cecal microbiota, as observed by a strong decrease in alpha diversity. A significant decrease in Firmicutes, particularly members of the order Clostridiales, was observed in FXR KO mice (P<0.05 and FDR<5%, ANOVA). While FXR deficiency strongly affects expression of genes related to immunity and bile acid metabolism, as well as the composition of the microbiome; however, its deficiency was not able to produce significant histopathological changes in the absence of H. hepaticus infection.

Indexed as

Helicobacter hepaticusAnimalsHelicobacter InfectionsHepatitisLiver NeoplasmsMiceMice, KnockoutNeoplasm ProteinsPrecancerous ConditionsReceptor, Farnesoid X-ActivatedReceptors, Cytoplasmic and NuclearNeoplasm ProteinsReceptor, Farnesoid X-ActivatedReceptors, Cytoplasmic and Nuclear

Identifiers

PMID25184625
PMCPMC4153687
OpenAlexW2122396791

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.